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A large number of potentially pathogenic non-tuberculous mycobacteria (NTM) encoun-
tered in the clinical laboratory makes it necessary to identify their species to ensure appro-
priate treatment. However, labor-intensive conventional methods of speciation are not
used in every laboratory, and hence NTM infections are often ignored. Polymerase chain
reaction (PCR) restriction analysis (PRA) was applied in this study for early identification
and speciation of mycobacterial species on 306 cultures of acid-fast bacilli isolated from
patients suspected of suffering from tuberculosis. Mycobacterium tuberculosis was identified
in 85.6% of the isolates. The NTM isolated most commonly was Mycobacterium kansasii/
gastri group (3.5%), followed byMycobacterium fortuitum (3.2%). Four of the M. fortuitum were
grown from cultures obtained on the same day, but from samples from different patients
and were probably laboratory contaminants. Mycobacterium intracellulare and Mycobacterium
avium were identified in 2.94% and 2.28% of the isolates, respectively. Three isolates of
M. avium and two isolates of M. intracellulare were obtained in repeated cultures from
sputum samples of the same patients and were thus pathogenic. A single isolate of
Mycobacterium abscessuswas obtained from a breast abscess. A rare pathogenMycobacterium
phocaicum was isolated from one patient with epididymitis. However, whether it was the
causative agent of epididymitis in this patient remains doubtful. The results of this study
highlight the importance of speciation of mycobacteria for appropriate diagnosis and the
importance of including molecular assays to augment conventional methods of diagnosis
of mycobacterial diseases for rapid identification of NTM so that these potential pathogens
are not overlooked in routine diagnostic procedures.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.-African Society for Mycobacteriology. All rights reserved.
17; fax: +91 11 27666549.
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NTM are widely distributed in nature and have been isolated
from soil, natural water, tap water, water used in showers and
surgical solutions [1]. Although Mycobacterium tuberculosis is
by far the most important mycobacterial species from a pub-
lic health perspective, other species of non-tuberculous
mycobacteria (NTM) are being encountered with increasing
frequency and new species are being identified. While not
all NTMs are pathogenic for humans, many are. Pathogenic
NTMs are usually less virulent thanM. tuberculosis, and poten-
tial pathogens may be isolated without obvious association
with a disease. On the contrary, species usually considered
benign may produce disease, especially in immunocompro-
mised individuals [2].
The prevalence of NTMs among world populations has sig-
nificant geographic variations that might occur even within
the same country [3]. Because of the large number of poten-
tially pathogenic NTMs that can be encountered in the clini-
cal laboratory, diagnosis of these organisms is required to
ensure appropriate treatment. However, diagnosis of NTM
infection is often difficult. Bacteriological, radiological and
clinical criteria to diagnose a disease are often not able to dis-
criminate between M. tuberculosis and NTM infection [4].
Moreover, a positive tuberculin skin test does not allow for a
distinction between NTM and M. tuberculosis infection [4].
Since labor-intensive conventional methods of speciation
are not used in every laboratory, NTM infections go unre-
ported and are thus ignored [5,6]. Hence, there is a need for
an assay which would overcome the disadvantages of bio-
chemical tests and would rapidly detect these organisms in
clinical specimens.
PCR restriction analysis (PRA) – which is simple and easy
to perform – was used in this study in order to get a prelimin-
ary assessment on the prevalence of NTM in the clinical spec-
imens received in the laboratory from non-HIV patients and
to understand the importance of including assays to identify
NTM in a routine clinical microbiology laboratory in North
India.
Materials and methods
Clinical isolates
A total of 306 clinical isolates were obtained from clinically
suspected patients of pulmonary tuberculosis (n = 304) and
extrapulmonary tuberculosis (n = 2) admitted at Rajan Babu
Institute of Respiratory Medicine and Tuberculosis, Delhi
and Vallabhbhai Patel Chest Institute (VPCI) during the time
period 2007–2010. Rajan Babu Institute of Respiratory Medi-
cine and Tuberculosis serves as a referral center for patients
with tuberculosis in North India and VPCI serves as a referral
hospital in North India for chest diseases. The patients were
adults P18 years old and were not co-infected with HIV. The
study was approved by the Institutional ethical committee,
and written and informed consent was taken from the
patients.Identification of cultures
The isolates were subjected to biochemical identification
using niacin, nitrate reduction and semi-quantitative catalase
tests by the standard procedure [7].
DNA extraction for PCR
DNA was extracted from the reference strain H37Rv and the
clinical isolates by boiling. Briefly, a loopful of mycobacterial
growth was transferred to a micro-centrifuge tube containing
100 ll of 1% TritonX-100 and 50 ll of sterile double distilled
water. The suspension was vortexed and boiled at 100 C for
30 min. The suspension was centrifuged at 8000 rpm for
10 min and the clear supernatant containing mycobacterial
DNA was taken for PCR.
Polymerase chain reaction (PCR)
PCR of the test samples was performed to amplify a 294 bp
region of the hsp65 gene. The primers used in the study
have been described previously [8]. H37Rv DNA and double
distilled water were used as positive and negative con-
trols, respectively. Briefly, mycobacterial DNA was amplified
in a 50 ll reactionmixture containing 240 lMdeoxynucleoside
triphosphates (Biotools B & M Labs, Madrid, Spain), 5 ll
of 10· Buffer, 2.5 mM of MgCl2 and 1.5 U of Taq DNA polymer-
ase [8].
Restriction analysis
Restriction digestion of the 294 bp product was carried out
with 1 U each of Sau96I and CfoI (Boehringer Mannheim
Biochemicals, Mannheim, Germany) in separate reactions as
described earlier, with slight modifications [8]. The restriction
digestion was carried out with 10 ll of the amplicon at 37 C
for 2 h. The digests were then electrophoresed in 10% non-
denaturing polyacrylamide gel with a 50 bp molecular weight
marker (Fermentas Life Sciences, Lithuania).
Sequencing
PCR products of 294 bp hsp65 gene of a subset of clinical iso-
lates were subjected to sequencing by Automated Sequencer
(Ocimum Biosolutions, Bangalore, India). Sequences were
identified by similarity using Blastn available at NCBI
(www.blast.ncbi.nlm.nih.gov/blast.cgi). Species identification
was confirmed if a 97% match was achieved with any se-
quence deposited in the database, according to the criteria
proposed by McNabb et al. [9].
Quality control
Quality laboratory practices were strictly followed at every
step. Sterile distilled water was used for reagent preparation.
Positive and negative controls were included with every new
batch of media and reagents.
Fig. 1 – (A and B) PRA profiles for mycobacterial species
detected in clinical isolates. (A) CfoI digests. Lane 1 is 50 bp
DNA marker. Lane 2 is the undigested positive control
H37Rv. Lane 10 is the digested positive control H37Rv. Lanes
3–9 are clinical isolates. Lanes 3, 6–8 are M. intracellulare.
Lane 4 is M. fortuitum. Lanes 5 and 9 are clinical isolates of
M. tuberculosis. (B) Sau96I digests. Lane 1 is 50 bp DNA
marker. Lane 2 is the undigested positive control H37Rv.
Lane 10 is the digested positive control H37Rv. Lanes 3–9 are
clinical isolates. Lanes 3, 6–8 are M. intracellulare. Lane 4 is
M. fortuitum. Lanes 5 and 9 are clinical isolates of M.
tuberculosis.
Table 1 – Isolation of non-tuberculous mycobacteria from
patients in North India.
Mycobacterium species Total no. identified (%)
M. tuberculosis complex 262 (85.6%)
M. kansasii/gastri 11 (3.5%)
M. fortuitum 10 (3.2%)
M. scrofulaceum 1 (0.32%)
M. avium 7 (2.28%)
M. intracellulare 9 (2.94%)
M. abscessus 1 (0.32%)
M .gordonae 4 (1.3%)
M. phocaicum 1 (0.32%)
Total 306
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NTM or atypical mycobacteria are environmental organisms
that are normally found in soil and water. The incidence of
NTM infection has increased in recent years [10–13], which
could partly be due to a changing epidemiology, an increase
in incidence of HIV co-infection or due to increased aware-
ness. However, resource deficient countries often overlook
infections owing to NTM because of a lack of extensive iden-
tification schemes that can be used in peripheral laboratories.
Moreover, phenotypic tests are often difficult to interpret,
cumbersome and have low specificity [14]. Hence, the impor-
tance of molecular assays to identify NTM cannot be under
estimated.
NTM have been reported from patients with HIV in North
India [15]. Therefore, PCR restriction analysis (PRA) was ap-
plied for early identification and speciation of mycobacterial
isolates in the laboratory in patients suspected to be suffering
from tuberculosis without HIV co-infection. Hsp65 PRA was
applied to the DNA extracted from cultures of acid-fast bacilli
(n = 306) obtained from patients suspected of suffering from
tuberculosis to get a preliminary assessment on the preva-
lence of NTM in the clinical specimens received in the labora-
tory. The maximum numbers of specimens were obtained
from patients with pulmonary tuberculosis; however, two
samples were from extrapulmonary sites viz. pus from a
breast abscess and a urine specimen. The isolates were ob-
tained during the time period 2007–2010 and were subjected
to biochemical identification using niacin, nitrate reduction
and semi-quantitative catalase tests [7]. PCR was performed
using published primers to obtain a 294 bp amplicon of the
hsp65 gene [8] and restriction digestion carried out with
Sau96I and CfoI (Fig. 1). The PCR amplicons of 51 clinical iso-
lates were confirmed by sequencing and the sequences iden-
tified by similarity using NCBI Blastn. Sequencing confirmed
39 of the 51 isolates to be M. tuberculosis complex and 12 iso-
lates as NTM in concordance with hsp65 PRA results.
Hsp65 PRA identifiedM. tuberculosis in 85.6% (n = 262) of the
306 isolates. Of the 44 (14.7%) NTM isolated in the laboratory, 2
were obtained from patients of extrapulmonary tuberculosis.
Mycobacterium kansasii/gastri group was the most common
NTM isolated and constituted 25% (n = 11) of all NTM.
Mycobacterium fortuitum constituted 22.7% (n = 10) of the
NTM isolated in our laboratory. Of these, 6 strains of
M. fortuitum were isolated from samples cultured the same
day and were not obtained on repeat cultures of the same
patients. These isolates were thus considered to be laboratory
contaminants. However, samples taken from various sites in
the laboratory did not yield any NTM. The other 4M. fortuitum
were obtained in repeat cultures and were considered
pathogenic. Another laboratory contaminant Mycobacterium
gordonae was identified in 4 samples (Table 1).
Mycobacterium intracellulare and Mycobacterium avium
constituted 20.45% (n = 9) and 15.9% (n = 7) of the NTM,
respectively. The clinical relevance of three pulmonary
M. avium isolates was established by the fact that they were
isolated from sputum samples obtained from the same
patient on three consecutive days, in pure culture. Similarly,
two of the M. intracellulare isolates were obtained from
sputum samples of the same patient on two different daysand were considered to be clinically relevant. Mycobacterium
abscessus was isolated from pus sample obtained from a
patient presenting with a breast abscess. An emerging
mycobacterial species, Mycobacterium phocaicum was isolated
Fig. 2 – PRA profiles for M. mucogenicum/M. phocaicum. The
clinical isolate was identified as M. phocaicum on
sequencing. Lane 1 is a 50 bp DNA marker. Lane 2 is the
undigested positive control H37Rv. Lane 3 is the CfoI digest
of the positive control H37Rv [Band sizes (bp): 122, 83, 72].
Lane 4 is the CfoI digest of the clinical isolate M. phocaicum
[Band sizes (bp): 172, 83]. Lane 5 is the Sau96I digest of
H37Rv [Band sizes (bp): 219, 54]. Lane 6 is the Sau96I digest
of the clinical isolate M. phocaicum [Band sizes (bp): 138, 102,
54].
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for tuberculous epididymitis. Curiously, this 82-year-old pa-
tient returned 6 years later with complaints of severe dysuria,
frequency and urethral irritation, leading to a suspicion of
reactivation of his earlier condition. The isolate obtained
was identified as Mycobacterium mucogenicum on hsp65 PRA
(Fig. 2). The restriction bands obtained with CfoI were 172 bp
and 83 bp. Restriction bands obtained with Sau96I were 138,
102 and 54 bp. An additional band was also visible at 219 bp
in the Sau96I restrict. The organism was tentatively identified
as M. mucogenicum on the basis of the algorithm published by
Wong et al. [8] and the PCR amplicon was sequenced to con-
firm the results of PRA. The strain was identified as M. phoca-
icum on sequencing of the hsp65 gene. Although M.
mucogenicum and M. phocaicum are phylogenetically close
and share sequence similarities [16], the algorithm created
by Wong et al. [8] does not mention the NTM M. phocaicum.
Since, the patient improved with conservative management,
the pathogenic potential of M. phocaicum in the present case
of epididymitis is doubtful. Very few cases of M. phocaicum
have been reported worldwide. This pathogen has been iso-
lated previously from blood stream infections in Texas [17]
and respiratory specimens from France [16]. This is the first
report of it being isolated from the urine specimen of a pa-
tient. One of the isolates obtained in this study was identified
as Mycobacterium scrofulaceum. Since no clinical details were
available for this patient, it could not be determined whether
or not this strain was pathogenic. Several patients may not be
able to get adequate treatment for NTM owing to a lack of
identification or owing to delayed diagnosis. In addition, it isimportant for the laboratory personnel to be aware of the
complete clinical details of patients prior to processing the
samples in order to assess the importance of isolating a par-
ticular organism and to rule out laboratory contamination.
Conclusions
A large number of NTMs were identified in patients with the
initial presumptive diagnosis of tuberculosis in the laboratory.
The application of rapid molecular assays would facilitate im-
proved diagnosis of NTMs by obviating the use of the more
cumbersome conventional diagnostic methods. In addition,
PRA or PCR-RFLP can identify a vast range of mycobacterial
species in a single experiment and it is also cost-effective
[8,18]. The results of this study reinforce the observation that
health centres and laboratories should take action to increase
the awareness of appropriate diagnosis of NTM. Commercial-
ization of NTM identification through quality-controlled kits
and inter-laboratory linkages shall provide the epidemiologi-
cal data to assess the importance and relevance of these iso-
lates collectively dismissed as environmental contaminants.
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